Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.

Alimentary pharmacology & therapeutics - 1 Aug 2004

Pierik M, Vermeire S, Steen K V, Joossens S, Claessens G, Vlietinck R, Rutgeerts P

Abstract excerpt

BACKGROUND: The role of tumour necrosis factor-alpha in the pathogenesis of inflammatory bowel disorders is well-known and is underscored by the effectiveness of antitumour necrosis factor-alpha treatment. Tumour necrosis factor-alpha exerts its effect by binding TNFR1 and TNFR2, which genes map to inflammatory bowel disorders susceptibility loci. AIMS AND METHODS: Since TNFR1 and TNFR2 are good candidate genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to C-Reactive Protein
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Gastrointestinal Agents

Share to Infliximab

Share to Receptors, Tumor Necrosis Factor

Share to Receptors, Tumor Necrosis Factor, Type I

Share to Receptors, Tumor Necrosis Factor, Type II

Source

Identifiers

PMID: 15274667
DOI: 10.1111/j.1365-2036.2004.01946.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.PMID 15274667Read ↗

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s diseaseSemantic proximity Read ↗

Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk.Semantic proximity Read ↗

Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients.Semantic proximity Read ↗

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.Semantic proximity Read ↗

Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes.Semantic proximity Read ↗

Association of tumor necrosis factor-&alpha; and -&beta; gene polymorphisms in inflammatory bowel diseaseSemantic proximity Read ↗

Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease.Semantic proximity Read ↗

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Semantic proximity Read ↗

Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Semantic proximity Read ↗

Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

Cytokine gene polymorphisms in inflammatory bowel disease.Semantic proximity Read ↗

Association between TNF-α rs1799724 and rs1800629 polymorphisms and the risk of Crohn's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.